Gabapentin News and Research

RSS
Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain.
Yale University: Gabapentin clinical study on epilepsy may have been a 'seeding trial'

Yale University: Gabapentin clinical study on epilepsy may have been a 'seeding trial'

Gabapentin medication induces anorgasmia in older and elderly patients

Gabapentin medication induces anorgasmia in older and elderly patients

Ideal psychotropic drug may cause physical dependence

Ideal psychotropic drug may cause physical dependence

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

New guideline on most effective treatments for diabetic nerve pain

New guideline on most effective treatments for diabetic nerve pain

GlaxoSmithKline, XenoPort receive FDA approval for Horizant to treat RLS

GlaxoSmithKline, XenoPort receive FDA approval for Horizant to treat RLS

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

Depomed completes patient enrollment in Breeze 3 Serada Phase 3 trial to treat menopausal hot flashes

Depomed completes patient enrollment in Breeze 3 Serada Phase 3 trial to treat menopausal hot flashes

Sweden's TLV confirms reimbursement for Qutenza patch for treatment of peripheral neuropathic pain

Sweden's TLV confirms reimbursement for Qutenza patch for treatment of peripheral neuropathic pain

FDA approves Matrix Labs generic Neurontin ANDA

FDA approves Matrix Labs generic Neurontin ANDA

EpiCept 2010 fourth quarter net loss is $0.06 per share

EpiCept 2010 fourth quarter net loss is $0.06 per share

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

FDA approves GRALISE Tablets for treatment of PHN

FDA approves GRALISE Tablets for treatment of PHN

Unintended direct conflict between pharmaceutical marketing and public health

Unintended direct conflict between pharmaceutical marketing and public health

Research on fruit flies reveal novel human pain gene

Research on fruit flies reveal novel human pain gene

XenoPort third quarter net loss decreases to $19.9 million

XenoPort third quarter net loss decreases to $19.9 million

FDA reviews GSK's response to Complete Response letter for Horizant

FDA reviews GSK's response to Complete Response letter for Horizant

New epilepsy drugs give more options, but make treatment decisions more complex: Epilepsy specialist

New epilepsy drugs give more options, but make treatment decisions more complex: Epilepsy specialist

Study finds non-hormonal therapies can relieve hot flashes in women with breast cancer

Study finds non-hormonal therapies can relieve hot flashes in women with breast cancer

Depomed announces SPA agreement with FDA for Serada Phase 3 trial for menopausal hot flashes

Depomed announces SPA agreement with FDA for Serada Phase 3 trial for menopausal hot flashes